USA - NASDAQ:LQDA - US53635D2027 - Common Stock
The current stock price of LQDA is 23.78 USD. In the past month the price decreased by -12.86%. In the past year, price increased by 139.1%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 46.56 | 711.73B | ||
JNJ | JOHNSON & JOHNSON | 17.62 | 424.33B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 15.54 | 272.83B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.89 | 237.97B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.18 | 236.50B | ||
MRK | MERCK & CO. INC. | 10.59 | 203.59B | ||
PFE | PFIZER INC | 7.09 | 136.62B | ||
SNY | SANOFI-ADR | 10.61 | 116.19B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.69 | 91.64B | ||
GSK | GSK PLC-SPON ADR | 8.92 | 81.93B | ||
ZTS | ZOETIS INC | 23.45 | 64.65B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.93 | 47.56B |
Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 157 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
LIQUIDIA CORP
419 Davis Drive, Suite 100
Morrisville NORTH CAROLINA 27560 US
CEO: Neal Fowler
Employees: 157
Phone: 19193284400
The current stock price of LQDA is 23.78 USD. The price decreased by -3.61% in the last trading session.
The exchange symbol of LIQUIDIA CORP is LQDA and it is listed on the Nasdaq exchange.
LQDA stock is listed on the Nasdaq exchange.
15 analysts have analysed LQDA and the average price target is 37.4 USD. This implies a price increase of 57.28% is expected in the next year compared to the current price of 23.78. Check the LIQUIDIA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LIQUIDIA CORP (LQDA) has a market capitalization of 2.05B USD. This makes LQDA a Mid Cap stock.
LIQUIDIA CORP (LQDA) currently has 157 employees.
LIQUIDIA CORP (LQDA) has a support level at 13.12 and a resistance level at 23.78. Check the full technical report for a detailed analysis of LQDA support and resistance levels.
The Revenue of LIQUIDIA CORP (LQDA) is expected to grow by 336.74% in the next year. Check the estimates tab for more information on the LQDA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LQDA does not pay a dividend.
LIQUIDIA CORP (LQDA) will report earnings on 2025-11-11, after the market close.
LIQUIDIA CORP (LQDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.7).
The outstanding short interest for LIQUIDIA CORP (LQDA) is 23.49% of its float. Check the ownership tab for more information on the LQDA short interest.
ChartMill assigns a technical rating of 8 / 10 to LQDA. When comparing the yearly performance of all stocks, LQDA is one of the better performing stocks in the market, outperforming 96.41% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to LQDA. Both the profitability and financial health of LQDA have multiple concerns.
Over the last trailing twelve months LQDA reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS decreased by -8.28% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -54.96% | ||
ROE | -931.4% | ||
Debt/Equity | 9.84 |
15 analysts have analysed LQDA and the average price target is 37.4 USD. This implies a price increase of 57.28% is expected in the next year compared to the current price of 23.78.
For the next year, analysts expect an EPS growth of 2.85% and a revenue growth 336.74% for LQDA